DEA's proposed rulemaking to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act remains stalled without a final rule, despite HHS's August 2023 scientific recommendation affirming accepted medical uses and President Trump's December 2025 executive order directing Attorney General Pam Bondi to expedite the process. Trader sentiment reflects ongoing procedural hurdles, highlighted by Rep. Steve Cohen's March 27 letter pressing Bondi and DEA Administrator Terry Cole for a timeline amid reports of Bondi's potential replacement by Lee Zeldin, whose congressional record shows mixed cannabis positions. Key factors include possible administrative hearings requested by opponents, 90-day status reports, and final Federal Register publication, with no substantive advances in the past 30 days keeping resolution uncertain.
基於Polymarket數據的AI實驗性摘要 · 更新於$285,685 交易量
2026-03-31
6月30日
13%
12月31日
40%
$285,685 交易量
6月30日
$11,140 交易量
13%
12月31日
$9,662 交易量
40%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.DEA's proposed rulemaking to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act remains stalled without a final rule, despite HHS's August 2023 scientific recommendation affirming accepted medical uses and President Trump's December 2025 executive order directing Attorney General Pam Bondi to expedite the process. Trader sentiment reflects ongoing procedural hurdles, highlighted by Rep. Steve Cohen's March 27 letter pressing Bondi and DEA Administrator Terry Cole for a timeline amid reports of Bondi's potential replacement by Lee Zeldin, whose congressional record shows mixed cannabis positions. Key factors include possible administrative hearings requested by opponents, 90-day status reports, and final Federal Register publication, with no substantive advances in the past 30 days keeping resolution uncertain.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
市場開放時間： Feb 7, 2026, 5:04 PM ET
交易量
$285,685結束日期
2026-03-31市場開放時間
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.DEA's proposed rulemaking to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act remains stalled without a final rule, despite HHS's August 2023 scientific recommendation affirming accepted medical uses and President Trump's December 2025 executive order directing Attorney General Pam Bondi to expedite the process. Trader sentiment reflects ongoing procedural hurdles, highlighted by Rep. Steve Cohen's March 27 letter pressing Bondi and DEA Administrator Terry Cole for a timeline amid reports of Bondi's potential replacement by Lee Zeldin, whose congressional record shows mixed cannabis positions. Key factors include possible administrative hearings requested by opponents, 90-day status reports, and final Federal Register publication, with no substantive advances in the past 30 days keeping resolution uncertain.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
交易量
$285,685結束日期
2026-03-31市場開放時間
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...DEA's proposed rulemaking to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act remains stalled without a final rule, despite HHS's August 2023 scientific recommendation affirming accepted medical uses and President Trump's December 2025 executive order directing Attorney General Pam Bondi to expedite the process. Trader sentiment reflects ongoing procedural hurdles, highlighted by Rep. Steve Cohen's March 27 letter pressing Bondi and DEA Administrator Terry Cole for a timeline amid reports of Bondi's potential replacement by Lee Zeldin, whose congressional record shows mixed cannabis positions. Key factors include possible administrative hearings requested by opponents, 90-day status reports, and final Federal Register publication, with no substantive advances in the past 30 days keeping resolution uncertain.
基於Polymarket數據的AI實驗性摘要 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions